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Boston, MassTABLE 1. Laboratory and hemodynamic data
Laboratory values Admission
Pre-
thrombolysis
Post-
thrombolysis
Creatinine (mg/dL) 1.57 4.0 1.35
Hemoglobin (g/dL) 14.4 10.0 11.3
LDH (IU/L) 244 1785
Plasma-free Hgb (mg/dL) 3.2 12.9
Haptoglobin (mg/dL) 3
Total bilirubin (mg/dL) 0.8 1.2 1.0
Hemodynamics
Right atrial (mm Hg) 18 20 16
Pulmonary artery
(mean; mm Hg)
38/20 (26) 48/21 (29) 38/18 (25)
Pulmonary
wedge (mm Hg)
18 16 16
LV (mm Hg) n/a 95/12 38/10
PA saturation 45% 42% 64%
Cardiac index (L/min/m2) 1.3 1.2 2.7
Hgb, Hemoglobin; LDH, lactate dehydrogenase; LV, left ventricle; PA, pulmonary
artery.Left ventricular assist devices (LVADs) improve the sur-
vival and quality of life in patients with refractory heart fail-
ure compared with optimal medical therapy. Compared
with pulsatile LVADs (p-LVADs), continuous-flow LVADs
(cf-LVADs) demonstrate better survival with fewer
device-related complications.1 However, the blood-contact
surfaces of the p-LVADs promote the formation of a pseu-
dointima that reduces thrombogenicity, whereas the impel-
ler cf-LVADs do not generate a pseudointima and may have
a higher rate of pump thrombosis.2 Experience with
cf-LVAD thrombosis is limited.Although thrombolytic ther-
apy has been described with axial-flow devices,3,4 there are
no reports of thrombolysis with cf-LVADs.
TheHeartWare system (HeartWare International Inc, Fra-
mingham, Mass) is a novel cf-LVAD that is implanted
within the pericardial space and that generates up to 10
L/min of flow. The HeartWare device is being investigated
as a bridge to transplantation in a multicenter US clinical
trial. The target international normalized ratio for the Heart-
Ware LVAD is 2 to 3. The risk of pump thrombosis associ-
ated with the HeartWare LVAD is unknown. We describe
the management of a thrombotic HeartWare LVAD obstruc-
tion using intraventricular thrombolytics.CLINICAL SUMMARY
A 57-year-old man with nonischemic cardiomyopathy
underwent HeartWare LVAD implantation as a bridge to
transplant. Five months later, the patient gained weight
and dyspnea worsened. Admission LVAD speed was 2800
rpm with an estimated flow of 4.8 L/min. Mean blood pres-
sure was 82 mm Hg. The patient’s international normalized
ratio was subtherapeutic at 1.4 because of medicalFrom the Divisions of Cardiologya and Cardiothoracic Surgery,b Tufts Medical Cen-
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echocardiogram revealed a midline septum, intermittently
opening aortic valve, and decompressed left ventricle
(LV). Right-sided heart catheterization confirmed low car-
diac output and elevated filling pressures (Table 1). The pa-
tient initially responded well to intravenous milrinone and
diuresis.
Six days later, LVADflowdecreased from4.4 to 2.8L/min
without a change in pump speed or blood pressure. Over
a 24-hour period, worsening pulmonary congestion, im-
paired renal function, and hemolysis were observed
(Table 1). Logged waveform files suggested an obstructive
pattern of reduced flow and increased power requirement.
During a gradual increase in pump speed (ramped study),
echocardiography demonstrated continuous opening of
the aortic valve and no change in LV end-diastolic dimen-
sion or septal position (Table 2). Maximizing pump speed
did not augment flow despite an increase in power use,
and the LV remained dilated, thereby confirming obstruc-
tion of pump flow. Echocardiography did not identify an
obvious source of obstruction; however, shadowing from
the LVAD inflow cannula prevented complete exclusion
of an LV thrombus. A non-contrast chest computed tomog-
raphy scan excluded outflow cannula kinking or aberrantery c September 2011
TABLE 2. Ramped study
Speed (rpm) Flow (L/min) Power Aortic valve opening Mitral regurgitation Septum Left ventricular size
Admission
2800 4.8 4.8 Intermittent Mild Midline Normal
Ramped speed study
3000 3.6 5.2 Continuous Mild Right-shift Dilated
3100 3.6 5.6 Continuous Mild Right-shift Dilated
3200 3.8 6.1 Continuous Mild Right-shift Dilated
3300 3.8 6.4 Continuous Mild Right-shift Dilated
3400 3.8 7.1 Continuous Mild Right-shift Dilated
3500 4.1 7.8 Continuous Mild Right-shift Dilated
3600 4.1 8.3 Continuous Mild Right-shift Dilated
Post-thrombolysis
3000 4.5 4.8 Closed Mild Left-shift Decompressed
Brief Technique Reportspositioning of the inflow cannula toward the septum or LV
free wall.
The patientwas referred for intraventricular administration
of thrombolytics. The LVwas accessed via the right radial ar-
tery using a 6F pigtail catheter (Figure 1). Baseline hemody-
namics demonstrated a normal LV pressure of 93/13 mmHg.
Ventriculography confirmed the absence of flow through the
LVAD. Alteplase was administered at a rate of 1 mg/min.
After 37 minutes, LV pressure spontaneously reduced to
40/8 mm Hg and LVAD flow improved to 4.2 L/min
(Figure 2).
Over a 12-hour period, urine output increased and trig-
gered suctionevents requiringfluid resuscitationanda reduc-
tion in pump speed.Decompression of theLVwas confirmed
with echocardiography. Threeweeks later, the patient under-
went successful orthotopic heart transplantation. After ex-
plant, the impeller showed no evidence of chronic thrombus.DISCUSSION
Device-associated thrombosis is a life-threatening com-
plication of cf-LVAD support. The incidence of device
thrombosis in axial-flow LVADs is reported to be 0.02FIGURE 1. A, HeartWare (HeartWare International Inc, Framingham, Mass)
image showing a 6F pigtail catheter (*) in close proximity to the HeartWare LV
The Journal of Thoracic and Caevents per patient year.1 The rate of thrombosis with centrif-
ugal cf-LVADs is unknown. The origin of device thrombo-
sis may involve in situ device thrombogenesis or migration
of a thrombus into the inflow cannula. Sudden changes in
pump parameters are more consistent with ingested throm-
bus, whereas gradual increases in power and reduced flow
suggest in situ thrombogenesis. Subtherapeutic anticoagu-
lation, retained LVor left atrial thrombus, low pump speeds
(<3.0 L/min), atrial fibrillation, bacteremia, and preexisting
hypercoaguable states may predispose patients to cf-LVAD
thrombosis. Management of device thrombosis includes de-
vice replacement or thrombolysis. Pump replacement is as-
sociated with high morbidity and mortality.2 Successful use
of a glycoprotein IIB-IIIA inhibitor for the management of
cf-LVAD thrombosis5 has been reported; however, continu-
ous infusion for 4 days was required for resolution. Man-
agement of pump thrombosis with the newer centrifugal
cf-LVADs has yet to be reported.CONCLUSIONS
Bleeding is a risk of thrombolytic therapy, including
intracranial hemorrhage. A potential advantage ofLVAD after implantation. B, Right angle oblique plane cineangiographic
AD inflow cannula (#). HW, HeartWare.
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FIGURE 2. Left ventricular (LV) and pulmonary artery (PA) hemody-
namic tracings before (A) and after (B) thrombolysis.
Brief Technique Reportsintracavitary thrombolysis may be the reduced dose of drug
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in the management of end-stage heart failure, standardiza-
tion of the percutaneous management of device thrombosis
may be necessary.References
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Lung Transplant. 2008;27:925-7.Video-assisted thoracoscopic surgical tracheobronchoplasty
for tracheobronchomalaciaDavid G. Tse, MD,a Sukgu M. Han, MD,a Burawit Charuworn, MD,b and Eric S. Kaufer, MD,b
Los Angeles, CalifThe surgical treatment of tracheobronchomalacia has
continued to evolve since the operative interventions for tra-
cheomalacia described in 1954 by Nissen.1 Recent experi-
ence with polypropylene mesh in the management of
tracheobronchomalacia has demonstrated satisfactory
long-term results.2,3 We report 2 cases of video-assisted
thoracoscopic surgical tracheobronchoplasty combinedwith airway stent placement for the treatment of
tracheobronchomalacia.CLINICAL SUMMARIES
Patient 1
A 56-year-old man with a history of severe chronic ob-
structive pulmonary disease had undergone 6 hospitaliza-
tions for respiratory failure during the previous year. He
reported decreased exercise tolerance and inability to clear
airway secretions. Results of pulmonary function tests were
suggestive of intrathoracic large airway obstruction. Flexi-
ble bronchoscopy demonstrated severe tracheobronchoma-
lacia with collapse of the entire left mainstem bronchus.
Dynamic computed tomographic chest scan showed expira-
tory collapse of the central airways (Figure 1). A right
video-assisted thoracoscopic surgical tracheobronchoplasty
of the trachea, right mainstem bronchus and bronchus
intermedius was performed with polypropylene mesh. Theery c September 2011
